Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -0.55% and Operating profit at -2.92% over the last 5 years
2
Flat results in Jun 25
3
With ROE of 8.92%, it has a expensive valuation with a 2.05 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 420,221 Million (Mid Cap)
23.00
NA
0.00%
-0.33
8.67%
2.02
Revenue and Profits:
Net Sales:
36,411 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,540 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.59%
0%
-4.59%
6 Months
-6.69%
0%
-6.69%
1 Year
-13.52%
0%
-13.52%
2 Years
-20.76%
0%
-20.76%
3 Years
-37.56%
0%
-37.56%
4 Years
-43.1%
0%
-43.1%
5 Years
-58.39%
0%
-58.39%
Kobayashi Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.55%
EBIT Growth (5y)
-2.92%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.81
Tax Ratio
23.82%
Dividend Payout Ratio
75.32%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.70%
ROE (avg)
10.01%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.05
EV to EBIT
15.97
EV to EBITDA
11.60
EV to Capital Employed
2.55
EV to Sales
2.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.96%
ROE (Latest)
8.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
36,411.00
36,651.00
-0.65%
Operating Profit (PBDIT) excl Other Income
6,239.00
6,512.00
-4.19%
Interest
8.00
13.00
-38.46%
Exceptional Items
-2,410.00
-4,315.00
44.15%
Consolidate Net Profit
1,540.00
460.00
234.78%
Operating Profit Margin (Excl OI)
113.00%
121.20%
-0.82%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -0.65% vs -8.73% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 234.78% vs -89.20% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
165,600.00
173,455.00
-4.53%
Operating Profit (PBDIT) excl Other Income
32,883.00
31,838.00
3.28%
Interest
28.00
29.00
-3.45%
Exceptional Items
-13,687.00
-300.00
-4,462.33%
Consolidate Net Profit
10,071.00
20,338.00
-50.48%
Operating Profit Margin (Excl OI)
150.10%
148.60%
0.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -4.53% vs 4.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -50.48% vs 1.58% in Dec 2023
About Kobayashi Pharmaceutical Co., Ltd. 
Kobayashi Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






